MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature

BACKGROUND: Antibodies to human full-length myelin oligodendrocyte glycoprotein (MOG-IgG) as detected by new-generation cell-based assays have recently been described in patients presenting with acute demyelinating disease of the central nervous system, including patients previously diagnosed with m...

Descripción completa

Detalles Bibliográficos
Autores principales: Jarius, S., Ruprecht, K., Stellmann, J. P., Huss, A., Ayzenberg, I., Willing, A., Trebst, C., Pawlitzki, M., Abdelhak, A., Grüter, T., Leypoldt, F., Haas, J., Kleiter, I., Tumani, H., Fechner, K., Reindl, M., Paul, F., Wildemann, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859439/
https://www.ncbi.nlm.nih.gov/pubmed/29554927
http://dx.doi.org/10.1186/s12974-018-1108-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859439/
https://www.ncbi.nlm.nih.gov/pubmed/29554927
http://dx.doi.org/10.1186/s12974-018-1108-6

Ejemplares similares